Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario

Renal cell carcinoma (RCC) represents the 12th most common cancer worldwide and the third most common newly diagnosed urogenital cancer after prostate cancer and urothelial carcinoma [1]. Standard treatment for localized non-metastatic RCC (stage I-III) is radical or partial nephrectomy. After radical surgery, patients with stage II-III have a substantial risk of relapse, which is estimated at around 35% [2,3]. The risk of disease recurrence is even greater in those patients who received resection of a metastatic lesion, a condition defined as “M1 with no evidence of disease (M1 NED)” [4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research